RE:When will we have the data...Stevero,
Here is a
summary I posted on Agoracom the other day on expected order of events and timelines to complete BETonMACE. Tada also provided excellent insight in
this post into timing of adjudication and follow ups. In my opinion, the announcement that should come first in Q1 '19 will be hitting 250 events/end of dosing. After that, the dominoes start falling and the bookends narrow. More clarity should come at
Biotech Showcase in 10 days.
As for shareprice if it "get the nod".......take a look at current
analyst reports and also check out what the recent REDUCE-IT cardiovascular outcomes trial for Vascepa did for Amarin shareprice after top-line and full data release. Also, check out how much excitement the SGLT2 inhibitors and GLP-1R agonists have generated and ask yourself how much a drug would be worth that elicits even greater MACE reduction in high CVD risk type 2 diabetics than these classes of drugs. SoutherTierTom is having a hard time grasping with a 600 million valuation. Soon enough, that will be an irrelevant question. A better question is how many billions will the market cap be if BETonMACE meets its primary endpoint? On the flip side, look out below if BETonMACE fails.
BearDownAZ